Drug
Nbi 1065845
Nbi 1065845: highest development phase Phase 3, developed by Neurocrine Biosciences. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Neurocrine Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| NBI-1065845 NCT06911112 | Phase 3 | Major Depressive Disorder |
| NBI-1065845 NCT06966401 | Phase 3 | Major Depressive Disorder |
| NBI-1065845 NCT06963021 | Phase 3 | Major Depressive Disorder |
| NBI-1065845 NCT05203341 | Phase 2 | Major Depressive Disorder |
Latest
No recent events.
Follow Nbi 1065845 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.